NEWS & MEDIA

Image Alt Text

NEOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE IIB CLINICAL STUDY OF IFNα Kinoid IN LUPUS

Company Expects the Availability of Results from the Study in Q2 2018

 Paris and Boston, June 20, 2017 – 7:00 AM CET – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced
the completion of patient enrollment for its phase IIb clinical study, IFN-K-002, evaluating IFNα Kinoid for the treatment of lupus.

Read More

EOVACS ANNOUNCES THE COMPLETION OF PATIENT ENROLLMENT IN PHASE...

USE OF EQUITY LINE

Paris and Boston, June 1, 2017 – 8:00 AM CET – Neovacs (Alternext Paris: ALNEV) – Neovacs announces that it has...

NEOVACS AND LUPUS EUROPE JOIN VOICES ON WORLD LUPUS DAY

In order to raise awareness about lupus, the progress made in the development of new treatments, and the importance of...

NEOVACS TO PRESENT CLINICAL DEVELOPMENT UPDATE ON IFNα KINOID...

At the 2nd Global Conference on Myositis May 5-8, 2017 – in Potomac, USA Paris and Boston, May 4, 2017 – 8:00 AM...

Neovacs reports FY 2016 financial results

▪ IFNα Kinoid to treat Lupus received “Fast Track” designation from FDA; Phase IIb ongoing ▪ Extended IFNα...

Neovacs to present kinoid technology and its clinical outlooks...

Paris and Boston, March 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the...

Neovacs and Biosense Global LLC sign option agreement worth up...

 – Neovacs receives an upfront fee and is eligible for additional milestone payments and double digit sales...

NEOVACS ISSUED NEW BROAD PATENT IN CHINA FOR IFNα KINOID...

Paris, February 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapy for the...

Neovacs Announces Independent Data and Safety Monitoring...

...

NEOVACS TO COLLABORATE WITH THE SUNNYBROOK RESEARCH INSTITUTE...

Paris and Boston, January 5th, 2017 – Neovacs (Alternext Paris: ALNEV)     Neovacs (Alternext Paris: ALNEV)...

NEOVACS REPORTS FIRST POSITIVE IMMUNOGENICITY RESULTS FOR...

Paris and Boston, January 25, 2017 – Neovacs (Alternext Paris: ALNEV),       a leader in active...